The Experts below are selected from a list of 126642 Experts worldwide ranked by ideXlab platform
Karl Y Bilimoria - One of the best experts on this subject based on the ideXlab platform.
-
acinar cell carcinoma of the pancreas in the united states prognostic factors and comparison to ductal adenocarcinoma
Journal of Gastrointestinal Surgery, 2008Co-Authors: Max C Schmidt, Karl Y Bilimoria, Jesus M. Matos, David J Bentrem, Mark S Talamonti, Keith D. LillemoeAbstract:Introduction Pancreatic acinar cell carcinoma (ACC) is a Rare Tumor with poorly defined prognosis.
Razelle Kurzrock - One of the best experts on this subject based on the ideXlab platform.
-
Rare Tumor clinic the university of california san diego moores cancer center experience with a precision therapy approach
Oncologist, 2018Co-Authors: Shumei Kato, Kellie Kurasaki, Sadakatsu Ikeda, Razelle KurzrockAbstract:Author(s): Kato, Shumei; Kurasaki, Kellie; Ikeda, Sadakatsu; Kurzrock, Razelle | Abstract: BACKGROUND:Patients with Rare Tumors may lack approved treatments and clinical trial access. Although each Rare Tumor is uncommon, cumulatively they account for approximately 25% of cancers. We recently initiated a Rare Tumor Clinic that emphasized a precision medicine strategy. MATERIALS AND METHODS:We investigated the first 40 patients presenting at the Rare Tumor Clinic. Next-generation sequencing (NGS) of tissue and plasma-derived, circulating-Tumor DNA (ctDNA), and protein markers were assessed. RESULTS:Median age was 58 years (range, 31-78 years); 70% (28/40) were women; median number of previous systemic therapies was 2 (range 0-7). The most common diagnoses were sarcoma (n = 7) for solid Tumors and Erdheim-Chester disease (n = 5) for hematologic malignancies. Twenty distinct diagnoses were seen. Examples of ultraRare Tumors included ameloblastoma, yolk sac liver Tumor, ampullary cancer, and Castleman's disease. Altogether, 32 of 33 patients (97%) with tissue NGS and 15 of 33 (45%) with ctDNA sequencing harbored ≥1 alteration. Overall, 92.5% of patients (37/40) had ≥1 actionable target based on either genomic (n = 32) or protein (n = 27) markers. In total, 52.5% (21/40) received matched therapy; 52.4% (11/21) achieved stable disease (SD) ≥6 months (n = 3), partial remission (PR; n = 6), or complete remission (CR; n = 2). Matched therapy resulted in significantly longer progression-free survival compared with last prior unmatched therapy (hazard ratio 0.26, 95% confidence interval 0.10-0.71, p = .008). CONCLUSION:Identifying genomic and protein markers in patients with Rare/ultraRare Tumors was feasible. When therapies were matched, g50% of patients attained SD ≥6 months, PR, or CR. Further precision medicine clinical investigations focusing on Rare and ultraRare Tumors are urgently needed. IMPLICATIONS FOR PRACTICE:Although Rare Tumors are infrequent by definition, when all subtypes of Rare cancers are combined, they account for approximately 25% of adult malignancies. However, patients with Rare Tumors may lack approved treatments and clinical trial access. This paper describes an institutional a Rare Tumor Clinic focused on a precision medicine strategy. Performing genomics and protein analyses was feasible amongst patients with Rare cancers. Over 50% of patients attained SD ≥6 months, PR, or CR when they received matched therapy (genomically targeted and/or immunotherapy). Further studies investigating the efficacy of the precision therapy approach among Rare Tumors are warranted.
Constance A. Griffin - One of the best experts on this subject based on the ideXlab platform.
-
Clonal cytogenetic abnormalities and BCL2 rearrangement in interdigitating dendritic cell sarcoma.
Leukemia & lymphoma, 2006Co-Authors: Hassan Nayer, Kathleen M. Murphy, Anita L. Hawkins, Patricia P. Long, Maura L. Gillison, Michael J. Borowitz, Constance A. GriffinAbstract:Interdigitating dendritic cell sarcoma (IDCS) is an extremely Rare Tumor of interdigitating dendritic cell origin. While lymph node is the most common site of involvement, extranodal presentations,...
Shumei Kato - One of the best experts on this subject based on the ideXlab platform.
-
Rare Tumor clinic the university of california san diego moores cancer center experience with a precision therapy approach
Oncologist, 2018Co-Authors: Shumei Kato, Kellie Kurasaki, Sadakatsu Ikeda, Razelle KurzrockAbstract:Author(s): Kato, Shumei; Kurasaki, Kellie; Ikeda, Sadakatsu; Kurzrock, Razelle | Abstract: BACKGROUND:Patients with Rare Tumors may lack approved treatments and clinical trial access. Although each Rare Tumor is uncommon, cumulatively they account for approximately 25% of cancers. We recently initiated a Rare Tumor Clinic that emphasized a precision medicine strategy. MATERIALS AND METHODS:We investigated the first 40 patients presenting at the Rare Tumor Clinic. Next-generation sequencing (NGS) of tissue and plasma-derived, circulating-Tumor DNA (ctDNA), and protein markers were assessed. RESULTS:Median age was 58 years (range, 31-78 years); 70% (28/40) were women; median number of previous systemic therapies was 2 (range 0-7). The most common diagnoses were sarcoma (n = 7) for solid Tumors and Erdheim-Chester disease (n = 5) for hematologic malignancies. Twenty distinct diagnoses were seen. Examples of ultraRare Tumors included ameloblastoma, yolk sac liver Tumor, ampullary cancer, and Castleman's disease. Altogether, 32 of 33 patients (97%) with tissue NGS and 15 of 33 (45%) with ctDNA sequencing harbored ≥1 alteration. Overall, 92.5% of patients (37/40) had ≥1 actionable target based on either genomic (n = 32) or protein (n = 27) markers. In total, 52.5% (21/40) received matched therapy; 52.4% (11/21) achieved stable disease (SD) ≥6 months (n = 3), partial remission (PR; n = 6), or complete remission (CR; n = 2). Matched therapy resulted in significantly longer progression-free survival compared with last prior unmatched therapy (hazard ratio 0.26, 95% confidence interval 0.10-0.71, p = .008). CONCLUSION:Identifying genomic and protein markers in patients with Rare/ultraRare Tumors was feasible. When therapies were matched, g50% of patients attained SD ≥6 months, PR, or CR. Further precision medicine clinical investigations focusing on Rare and ultraRare Tumors are urgently needed. IMPLICATIONS FOR PRACTICE:Although Rare Tumors are infrequent by definition, when all subtypes of Rare cancers are combined, they account for approximately 25% of adult malignancies. However, patients with Rare Tumors may lack approved treatments and clinical trial access. This paper describes an institutional a Rare Tumor Clinic focused on a precision medicine strategy. Performing genomics and protein analyses was feasible amongst patients with Rare cancers. Over 50% of patients attained SD ≥6 months, PR, or CR when they received matched therapy (genomically targeted and/or immunotherapy). Further studies investigating the efficacy of the precision therapy approach among Rare Tumors are warranted.
Chad J Creighton - One of the best experts on this subject based on the ideXlab platform.
-
genomics of chromophobe renal cell carcinoma implications from a Rare Tumor for pan cancer studies
Oncoscience, 2015Co-Authors: Kimryn Rathmell, Fengju Chen, Chad J CreightonAbstract:Chromophobe Renal Cell Carcinoma (ChRCC) is a Rare subtype of the renal cell carcinomas, a heterogenous group of cancers arising from the nephron. Recently, The Cancer Genome Atlas (TCGA) profiled this understudied disease using multiple data platforms, including whole exome sequencing, whole genome sequencing (WGS), and mitochondrial DNA (mtDNA) sequencing. The insights gained from this study would have implications for other types of kidney cancer as well as for cancer biology in general. Global molecular patterns in ChRCC provided clues as to this cancer's cell of origin, which is distinct from that of the other renal cell carcinomas, illustrating an approach that might be applied towards elucidating the cell of origin of other cancer types. MtDNA sequencing revealed loss-of-function mutations in NADH dehydrogenase subunits, highlighting the role of deregulated metabolism in this and other cancers. Analysis of WGS data led to the discovery of recurrent genomic rearrangements involving TERT promoter region, which were associated with very high expression levels of TERT, pointing to a potential mechanism for TERT deregulation that might be found in other cancers. WGS data, generated by large scale efforts such as TCGA and the International Cancer Genomics Consortium (ICGC), could be more extensively mined across various cancer types, to uncover structural variants, mtDNA mutations, themes of Tumor metabolic properties, as well as noncoding point mutations. TCGA's data on ChRCC should continue to serve as a resource for future pan-cancer as well as kidney cancer studies, and highlight the value of investigations into Rare Tumor types to globally inform principals of cancer biology.
